Vivos Therapeutics, Inc. (NASDAQ:VVOS) Given Average Recommendation of “Hold” by Brokerages

Shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) have been assigned an average recommendation of “Hold” from the five research firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $2.5833.

A number of equities research analysts have weighed in on VVOS shares. Ascendiant Capital Markets cut their target price on Vivos Therapeutics from $5.50 to $3.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Monday, April 20th. Finally, HC Wainwright cut their target price on Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating for the company in a research report on Friday, April 17th.

Insider Activity

In related news, major shareholder Michael C. Skaff purchased 1,353,625 shares of the company’s stock in a transaction on Tuesday, March 31st. The shares were bought at an average price of $1.34 per share, with a total value of $1,813,857.50. Following the completion of the acquisition, the insider owned 1,353,625 shares of the company’s stock, valued at approximately $1,813,857.50. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 2.10% of the company’s stock.

Institutional Trading of Vivos Therapeutics

Large investors have recently added to or reduced their stakes in the company. Acorn Wealth Advisors LLC acquired a new position in shares of Vivos Therapeutics in the fourth quarter worth $30,000. XTX Topco Ltd acquired a new stake in Vivos Therapeutics during the second quarter valued at $65,000. Sequoia Financial Advisors LLC purchased a new position in Vivos Therapeutics in the first quarter valued at about $28,000. B. Riley Wealth Advisors Inc. purchased a new position in Vivos Therapeutics in the second quarter valued at about $220,000. Finally, DRW Securities LLC grew its stake in Vivos Therapeutics by 179.5% in the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after purchasing an additional 74,441 shares in the last quarter. 26.35% of the stock is owned by institutional investors and hedge funds.

Vivos Therapeutics Stock Performance

Shares of NASDAQ VVOS opened at $0.66 on Monday. The company has a current ratio of 0.24, a quick ratio of 0.24 and a debt-to-equity ratio of 3.31. The stock has a 50 day simple moving average of $1.17 and a 200-day simple moving average of $1.77. The company has a market cap of $9.05 million, a PE ratio of -0.32 and a beta of 6.25. Vivos Therapeutics has a 12-month low of $0.65 and a 12-month high of $7.95.

Vivos Therapeutics (NASDAQ:VVOS) last issued its quarterly earnings data on Wednesday, April 15th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.08). The business had revenue of $3.82 million for the quarter, compared to analyst estimates of $7.10 million. Vivos Therapeutics had a negative return on equity of 849.22% and a negative net margin of 121.37%.During the same quarter in the prior year, the firm posted ($2.22) earnings per share. On average, equities research analysts forecast that Vivos Therapeutics will post -1.33 EPS for the current year.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.